GlassScriptPhysician profile
Julia Whitley Sheets
NPI 1356728497
$4,017.78
in general payments reported to CMS, 2019-2025
47 companies · $3,267 in 2025
The $3,267 reported for 2025 was more than what 75% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $59.83 · 2024: $691 · 2025: $3,267.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,880 · Education: $77.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,879.96 |
| Education | $77.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $429.81 | 2025 | Darzalex, Rybrevant, Erleada |
| Daiichi Sankyo INC. | $337.05 | 2024-2025 | Injectafer, Enhertu, Datroway |
| Genzyme Corporation | $287.75 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $248.80 | 2025 | |
| Pfizer INC. | $209.36 | 2024-2025 | |
| Incyte Corporation | $192.98 | 2024-2025 | Jakafi, Monjuvi, Pemazyre |
| Shield Therapeutics INC | $172.63 | 2024-2025 | |
| Abbvie INC. | $144.37 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $126.31 | 2025 | Imfinzi, Enhertu, Lynparza |
| Merck Sharp & Dohme LLC | $122.37 | 2025 | Keytruda, Welireg, Lynparza |
| Shockwave Medical, INC | $118.78 | 2025 | |
| Tersera Therapeutics LLC | $113.76 | 2025 | Zoladex, Xermelo, Quzyttir |
| Bayer Healthcare Pharmaceuticals INC. | $104.58 | 2024-2025 | |
| Eisai INC. | $95.79 | 2024-2025 | |
| Servier Pharmaceuticals LLC | $81.44 | 2025 |
Show all 47 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $77.90 | 2024-2025 | Opdivo |
| Genentech USA, INC. | $73.72 | 2025 | Venclexta |
| Sobi, INC | $69.61 | 2024-2025 | |
| Taiho Oncology, INC. | $63.18 | 2025 | |
| Amgen INC. | $59.83 | 2019 | |
| Karyopharm Therapeutics INC. | $54.30 | 2024-2025 | Xpovio |
| Lilly USA, LLC | $51.65 | 2024-2025 | Jaypirca, Verzenio, Retevmo |
| Astellas Pharma US INC | $51.25 | 2024-2025 | Xtandi, Padcev |
| Pharmacosmos Therapeutics INC. | $50.26 | 2025 | Monoferric |
| Alexion Pharmaceuticals, INC. | $49.04 | 2025 | Ultomiris |
| Tempus Ai, INC | $46.21 | 2024-2025 | Xt Cdx |
| Caris Mpi, INC. | $45.49 | 2025 | Mi Cancer Seek |
| Blueprint Medicines Corporation | $44.80 | 2024 | Ayvakit |
| Celgene Corporation | $43.71 | 2024 | Reblozyl |
| Boehringer Ingelheim Pharmaceuticals, INC. | $43.09 | 2025 | |
| Immunocore Limited | $36.22 | 2025 | Kimmtrak |
| Jazz Pharmaceuticals INC. | $35.76 | 2025 | |
| Adc Therapeutics America, INC. | $35.61 | 2025 | |
| Beone Medicines USA, INC. | $30.53 | 2025 | Brukinsa |
| Legend Biotech USA INC. | $28.51 | 2025 | Carvykti |
| Ipsen Biopharmaceuticals, INC | $27.11 | 2025 | Onivyde |
| Takeda Pharmaceuticals U.S.A., INC. | $25.06 | 2025 | Iclusig |
| Adaptive Biotechnologies Corporation | $24.48 | 2025 | Clonoseq |
| Beigene USA, INC. | $23.34 | 2025 | Tevimbra |
| Exelixis INC. | $22.25 | 2025 | Cabometyx |
| Array Biopharma INC | $19.20 | 2025 | Mektovi, Tukysa, Braftovi |
| Agios Pharmaceuticals, INC. | $19.12 | 2025 | Pyrukynd |
| Myriad Genetic Laboratories, INC. | $17.83 | 2024 | Myrisk |
| Geron Corporation | $17.66 | 2025 | Rytelo |
| Gilead Sciences, INC. | $15.47 | 2025 | Trodelvy |
| Abiomed | $15.05 | 2024 | Impella |
| Puma Biotechnology, INC. | $14.76 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Julia Sheets listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.